Results 31 to 40 of about 1,629 (148)

Successful outcome of second allogeneic bone marrow transplantation for blastic plasmacytoid dendritic cell neoplasm with MYC locus rearrangement

Leukemia Research Reports, 2019
A 62-year-old male was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) with a MYC rearrangement. Four months after the first unrelated bone marrow transplantation (BMT), he developed the relapsed BPDCN.
Takeharu Kato, Hidehiro Itonaga, Jun Taguchi, Junya Makiyama, Machiko Fujioka, Masataka Taguchi, Makiko Horai, Yasushi Sawayama, Daisuke Niino, Yoshitaka Imaizumi, Tomoko Hata, Shinichiro Yoshida, Kana Sakamoto, Kengo Takeuchi, Koichi Ohshima, Yasushi Miyazaki   +15 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm

Current Treatment Options in Oncology, 2019
While there is a high initial response rate with standard chemotherapeutic regimens for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the responses are typically not durable and this remains a very aggressive disease with generally poor outcomes.
Daniel, Kerr, Ling, Zhang, Lubomir, Sokol   +2 more
openaire   +4 more sources

Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications

Haematologica, 2010
Background Blastic plasmacytoid dendritic cell neoplasm is a rare malignancy that typically follows a highly aggressive clinical course in adults, whereas experience in children with this disease is very limited.Design and Methods This retrospective ...
Armin G. Jegalian, Nataliya P. Buxbaum, Fabio Facchetti, Mark Raffeld, Stefania Pittaluga, Alan S. Wayne, Elaine S. Jaffe   +6 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm Mimicking Erythema Nodosum: A Case Report

Annals of Internal Medicine: Clinical Cases, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), previously known as blastic natural killer cell lymphoma, is a rare, difficult-to-diagnose, and aggressive hematologic malignancy.
Marino Hirata, Nozomu Yoshino, Maya Takazawa, Hisashi Oshiro, Shinichi Kako, Hitoshi Sugawara   +5 more
doaj   +1 more source

Regimen of Azacitidine Combined with GemOx in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report

Xiehe Yixue Zazhi, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly malignant hematological tumor derived from the precursor cells of plasmacytoid dendritic cells.
CHEN Xiaojun, LIU Yanquan, HU Xiaomei, HUANG Surong, SHEN Jianzhen   +4 more
doaj   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm; A Report of Three Cases [PDF]

Iranian Journal of Medical Sciences, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematodermic myeloid malignancy that is known to be derived from plasmacytoid dendritic cells which are characterized by expression of CD4, CD56, and more specific markers such as CD123. Here,
Akbar Safaei, Ahmad Monabati, Maral Mokhtari, Freidoon Solhjoo, Mehdi Montazer   +4 more
doaj   +1 more source

Characterization of CD123 expression by mast cells in systemic mastocytosis with multicolor flow cytometry

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean, Tracy I. George, David P. Ng   +2 more
wiley   +1 more source

Indispensable role of immunophenotyping in diagnosing leukemic phase of blastic plasmacytoid dendritic cell neoplasm without cutaneous manifestation

Leukemia Research Reports, 2022
Blastic plasmacytoid dendritic cell neoplasm usually presents as skin lesions. Diagnostic error occurs when it primarily presents in leukemic phase without skin involvement.
Hareem Alam, Nabiha Saeed, Anila Rashid
doaj   +1 more source

Assessment of the Performance of Siemens Scopio Digital Morphology on Bone Marrow Aspirates in Onco‐Hematology

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Objectives Digital morphology (DM) systems assisted by artificial intelligence are increasingly being introduced into hematology laboratories; however, data on their performance in routine clinical practice for bone marrow aspirates (BMA) remain limited.
Gina Zini, John Marra, Elena Rossi, Silvia Bellesi, Nicoletta Pelliccioni, Giuseppe d'Onofrio, Patrizia Chiusolo   +6 more
wiley   +1 more source

Salivary Methotrexate as a Predictor of Oral Mucositis in Hematological Cancer Patients: A Phase II Randomized, Double‐Blind Clinical Trial

Oral Diseases, EarlyView.
ABSTRACT Objective To evaluate the efficacy of prophylactic photobiomodulation therapy (PBMT) in preventing oral mucositis (OM) and to assess serum and salivary methotrexate (MTX) levels as predictors of OM in adults receiving high‐dose methotrexate (HD‐MTX).
Letícia Rodrigues‐Oliveira, Carolina Guimarães Bonfim, Ana Leticia Mores, Natalia Rangel Palmier, Henrique Ballassini Abdalla, Juliana Trindade Clemente‐Napimoga, Iara Gonçalves Aquino, Maria Cecilia Querido de Oliveira, Maria Cláudia Cuzzullin, Aljomar Jose Vechiato Filho, Cesar Rivera, Tatiana Natasha Toporcov, Juliana Pereira, Luiz Alcino Gueiros, Rossana Veronica Mendoza López, Manoela Domingues Martins, Marcelo Lazzaron Lamers, Karina Morais‐Faria, Pablo Agustin Vargas, Alan Roger Santos‐Silva, Thais Bianca Brandão, Ana Carolina Prado‐Ribeiro   +21 more
wiley   +1 more source